THE SHORT ANSWER
CVS Caremark Wegovy Coverage: Quick Answer
Good News: Wegovy Is a Preferred GLP-1 on CVS Caremark
Wegovy has been a preferred GLP-1 (a class of weight loss medications) on CVS Caremark's commercial template formularies (lists of covered drugs) since July 1, 2025. From July 1, 2025 to September 30, 2026, Zepbound was nonpreferred or excluded on CVS Caremark’s most common commercial formularies, with Wegovy preferred; not every one of those formularies excluded Zepbound, and plan sponsors could customize.[1] Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize).
If your pharmacy benefits are managed by CVS Caremark, Wegovy may be covered, depending on your plan. Here's what to expect:
- Prior authorization (PA) likely — expect to need approval before coverage; ask your plan for its criteria
- BMI criteria apply — Typically BMI (body mass index) ≥30, or ≥27 with a comorbidity (related health condition like diabetes or high blood pressure)
- Tier placement and copays vary — they depend on your employer's plan
- Step therapy may apply — Some plans may require trying another drug first; check your plan’s criteria
Important: CVS Caremark is a pharmacy benefit manager (PBM), not an insurance company. Your employer or insurer contracts with CVS Caremark to manage prescription benefits. Coverage details depend on your specific employer's plan design—always verify with your HR department and CVS Caremark directly.
Why this matters: CVS Health says it serves about 88 million plan members (CVS Health, May 2026) and processes about 27% of U.S. prescription claims (2024 market-share estimate).[6] Their decision to prefer Wegovy can mean easier access for members whose plans follow the template formularies and cover weight-loss drugs.
For a complete overview of getting Wegovy covered regardless of insurer, see our full coverage guide or Is Wegovy Covered by Insurance?.
WHY THIS MATTERS FOR YOUR COVERAGE
Understanding CVS Caremark as a PBM
CVS Caremark is a pharmacy benefit manager (PBM)—a middleman between your insurance company and pharmacies. Understanding this distinction is key to navigating your Wegovy coverage:
| Role | What They Do | Examples |
|---|---|---|
| Insurance Company | Sets overall benefits, pays claims, decides what's covered | Blue Cross, Aetna, UnitedHealthcare, Cigna |
| Employer (Self-Funded) | May customize drug benefits beyond standard formulary | Large corporations, government entities |
| PBM (CVS Caremark) | Manages formulary, processes Rx claims, negotiates drug prices | CVS Caremark, Express Scripts, OptumRx |
Why Does This Matter?
CVS Caremark's formulary decisions affect many of its roughly 88 million plan members (per CVS Health, above)—but not everyone uniformly:
- Employers can customize — Self-funded employers can negotiate different tier placements or PA requirements
- Your insurer may have different rules — Some insurers contract with CVS Caremark but require different coverage terms
- Some employers exclude all GLP-1s — Even though Wegovy is a preferred GLP-1 on CVS Caremark, some employer plans exclude weight loss drugs entirely
How to Check Your Specific Coverage
Your ID card tells you who to call. Look for "Rx Bin" or "Pharmacy" on your card—if it shows CVS Caremark, your prescription benefits are managed by them. But your employer or insurer may have negotiated different terms.
Call both: (1) your HR department and (2) the number on your card.
2025 COVERAGE CHANGES
CVS Caremark Formulary & Tier Status
Here's the status of GLP-1 medications on CVS Caremark's commercial template formularies. Tiers and coverage still depend on your plan:
| Medication | Indication | Standard Formulary | Tier |
|---|---|---|---|
| Wegovy (semaglutide) | Weight loss | Preferred | Varies by plan |
| Zepbound (tirzepatide) | Weight loss | Additional preferred option on template formularies (Oct 1, 2026) | Varies by plan |
| Mounjaro (tirzepatide) | Type 2 diabetes | Check your plan | Varies by plan |
| Ozempic (semaglutide) | Type 2 diabetes | Check your plan | Varies by plan |
| Saxenda (liraglutide) | Weight loss | Check your plan | Varies by plan |
Why Did CVS Caremark Choose Wegovy?
CVS Caremark selected Wegovy as its preferred GLP-1 for weight loss effective July 1, 2025; until September 30, 2026, Zepbound was nonpreferred or excluded on some (its most common) commercial template formularies, not all. Members who had already tried Wegovy without success could ask for a formulary exception.[2]
Background: The Zepbound Class Action Lawsuits
In September 2025, two class action lawsuits were filed by Zepbound patients against CVS Caremark:[3][8]
- Larkin v. CVS Caremark (Sept. 3, 2025 – S.D.N.Y., Case No. 1:25-cv-07307)
- Hamburger v. CVS Caremark (Sept. 4, 2025 – D.D.C., Case No. 1:25-cv-03000)
Key allegations: The plaintiffs allege CVS prioritized rebate profits over patient outcomes by forcing Zepbound patients to switch to Wegovy. CVS Caremark has called the lawsuits "without merit."[9]
For Wegovy patients: These lawsuits don't affect your coverage—they were filed by patients who lost Zepbound access and were told to switch to Wegovy.
Call Script: Checking Your Coverage
Call Script for CVS Caremark
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Wegovy (semaglutide) covered on my specific employer plan for weight management?
- What tier is Wegovy on, and what's my estimated copay?
- Does my plan require prior authorization for Wegovy?
- What are the prior authorization requirements—BMI, comorbidities, weight management program?
- Can I get this coverage determination in writing?"
Pro tip: Call your HR department first. Some employers exclude weight loss medications entirely despite CVS Caremark's standard formulary—HR can confirm whether your specific plan covers GLP-1s.
CVS CAREMARK CRITERIA
Prior Authorization Requirements
Even though Wegovy is a preferred GLP-1 on CVS Caremark's template formularies, expect a prior authorization requirement. Requirements can include:
- BMI ≥30, or ≥27 with a comorbidity (type 2 diabetes, high blood pressure, or dyslipidemia/high cholesterol per FDA labeling)
- 6-month weight management program — participation in a program that includes diet, exercise, and lifestyle changes
- Chart notes documenting BMI measurements and any weight-related health conditions
- No contraindications — no personal or family history of medullary thyroid cancer or MEN2 (a rare genetic condition affecting hormone glands)
Official Novo Nordisk Resources
Novo Nordisk provides free tools for CVS Caremark patients:[7]
For complete prior auth preparation, see our Wegovy prior authorization guide →
Your GLP-1 coverage,
denied approved
If CVS Caremark denies your Wegovy exception request, Honest Care can help you build a strong appeal with evidence-backed documentation.
Denied by CVS Caremark?
Get Help NowYOUR OPTIONS
What to Do If Denied
Appeals Can Work
65%+ of insurance appeals succeed—meaning roughly 2 out of every 3 people who appeal get approved.[4] Yet fewer than 1 in 100 denied claims are ever appealed[5]—those who do have a real chance of getting coverage.
Common CVS Caremark Denial Reasons for Wegovy
- "Does not meet criteria" — BMI or comorbidity requirements not documented
- "Step therapy not completed" — Some plans require a documented weight-management program (or another treatment) first
- "Insufficient documentation" — Missing weight history or comorbidity records
- "Employer plan exclusion" — Some employers exclude weight loss medications entirely
What to Do:
Get the Denial in Writing
Request a written denial letter with the specific reason for denial.
Address the Specific Reason
Work with your doctor to provide missing documentation: BMI measurements, comorbidity diagnoses, or weight history records.
Request Peer-to-Peer Review
Your doctor can request a peer-to-peer review (a phone call between your doctor and CVS Caremark's medical director) to discuss why you need this medication.
File Your Appeal
For ACA-regulated and employer (ERISA) plans you have 180 days to file an internal appeal (your denial letter states your plan's exact deadline). Need help? Use Honest Care to build your appeal →
Alternative Pathways
Check Your Employer's Plan Design
Even with CVS Caremark as PBM, self-funded employers can customize coverage. Ask HR if your specific plan covers weight loss medications.
NovoCare Savings Programs
If your plan excludes weight loss drugs entirely, the Wegovy savings offer doesn't apply (No current Wegovy card price for plans that don’t cover it; self-pay pricing applies). NovoCare self-pay is $349/month ($399 for Wegovy HD 7.2 mg).
For complete appeal strategies, see our Wegovy appeals guide →
CVS CAREMARK WEGOVY COVERAGE
Frequently Asked Questions
Yes, Wegovy is a preferred GLP-1 for weight loss on CVS Caremark. As of July 1, 2025, CVS Caremark selected Wegovy as its preferred weight loss medication, while Zepbound was nonpreferred or excluded on some (its most common) commercial template formularies, not all, until September 30, 2026. Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize). Expect prior authorization and clinical criteria (BMI ≥30, or ≥27 with comorbidity). Your specific coverage depends on your employer's plan design—always verify with HR and CVS Caremark directly.
CVS Caremark says the change was made to provide "wider access to effective weight management treatment" by standardizing on one preferred medication. Two class action lawsuits filed by Zepbound patients allege the decision was driven by rebate negotiations—Novo Nordisk (Wegovy's maker) allegedly offered CVS Caremark more favorable terms than Eli Lilly (Zepbound's maker). CVS has called these lawsuits "without merit." For Wegovy patients, this formulary change is beneficial as it makes your medication the preferred option.
Even as a preferred GLP-1, expect Wegovy to require prior authorization (pre-approval from your insurer). Requirements can include: (1) BMI ≥30, or BMI ≥27 with at least one weight-related health condition (type 2 diabetes, high blood pressure, or high cholesterol per FDA labeling), (2) participation in a 6-month weight management program (diet, exercise, and lifestyle changes), (3) chart notes documenting BMI and health conditions, and (4) no contraindications such as personal/family history of medullary thyroid cancer or MEN2 syndrome (a rare genetic condition).
CVS Caremark is a pharmacy benefit manager (PBM), not an insurer. CVS Caremark processes about 27% of all U.S. pharmacy claims, making them one of the three largest PBMs alongside Express Scripts and OptumRx. Your employer or insurance company contracts with CVS Caremark to manage prescription drug benefits. This means: your insurer sets overall coverage rules, your employer may customize those rules (if self-funded), and CVS Caremark manages the formulary and processes pharmacy claims. When appealing, you may need to work with both CVS Caremark and your insurer.
First, request the denial reason in writing. Then file an internal appeal within the deadline in your denial letter (180 days for ACA-regulated and employer ERISA plans), including: documentation that you meet BMI criteria, evidence of weight-related health conditions, participation in a 6-month weight management program, and a Letter of Medical Necessity from your doctor. Your doctor can also request a peer-to-peer review (a phone call with CVS Caremark's medical director). Research shows 65%+ of insurance appeals succeed—meaning roughly 2 out of every 3 people who appeal get approved. Yet fewer than 1 in 100 patients ever appeal—so it's worth trying.
Some employers exclude all weight loss medications regardless of CVS Caremark's formulary preferences. If that's your situation, options include: (1) NovoCare self-pay pricing — the savings offer needs coverage, but self-pay is $349/month ($399 for Wegovy HD 7.2 mg); (2) Advocate during open enrollment — request your HR department add GLP-1 coverage; (3) Check if Wegovy's cardiovascular indication qualifies — if you are an adult with established cardiovascular disease and either obesity or overweight, coverage may be available for that FDA-approved indication rather than weight loss.
WHAT'S COMING
CVS Caremark Coverage Outlook for 2026
Wegovy remains a preferred GLP-1 on CVS Caremark's commercial template formularies, and Since October 1, 2026, Zepbound is back on CVS Caremark’s commercial template formularies as an additional preferred option (plan sponsors can customize). Employers and plans can customize their formulary, so check your own plan's formulary. Two class action lawsuits were filed by Zepbound patients in September 2025 (Larkin v. CVS Caremark and Hamburger v. CVS Caremark); Wegovy remains preferred on the template formularies. For Medicare policy updates, see our Medicare guide.
YOUR PATH FORWARD
What's Next
Wegovy Coverage: Other Major Insurers
Coverage depends on your insurance plan, not just your PBM. See insurer-specific guides:
- Aetna — Coverage varies; PA typically required
- Blue Cross Blue Shield — Varies by state/plan; restrictions common
- Cigna — Cigna plans may require step therapy; check your plan’s policy
- UnitedHealthcare — Coverage varies by plan; PA required
- Humana — Medicare and Medicaid plans only; Medicare members can use the Medicare GLP-1 Bridge
Other GLP-1 Medications at CVS Caremark
CVS Caremark's coverage varies by medication. Compare your options:
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedReferences
- CVS Caremark. (2025). "Enabling wider access to effective weight management treatment." business.caremark.com
- CVS Caremark. (2025). "CVS Caremark GLP-1 Formulary Changes - Zepbound Removal." business.caremark.com
- CNN. (2025). "CVS Caremark stopped covering a GLP-1 for obesity. Now there's a lawsuit." cnn.com
- American Medical Association. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org
- KFF. (2023). "Claims Denials and Appeals in ACA Marketplace Plans in 2023." kff.org
- Becker's Hospital Review. (2024). "Top PBMs by 2024 market share." beckershospitalreview.com
- Novo Nordisk. (2025). "Wegovy Coverage and Savings." wegovy.com
- U.S. District Court, Southern District of New York. (2025). "Larkin v. Caremark RX, LLC." Case No. 1:25-cv-07307. Filed September 3, 2025.
- Fierce Healthcare. (2025). "CVS Caremark hit with class-action lawsuit over decision to drop Zepbound from formulary." fiercehealthcare.com
Last updated October 6, 2026 · Key facts verified October 2, 2026 · Full page reviewed October 5, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.